Elucidation of the molecular mechanism of castration-resistant progression of prostate cancer and its application to precision oncology
| Project/Area Number |
16K11030
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Toho University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2016-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
|
|---|
| Keywords | 前立腺癌 / 去勢抵抗性前立腺癌 / ホルモン療法 / プロテオミクス / アンドロゲン受容体 / アビラテロン / エンザルタミド / 骨転移 / 酢酸アビラテロン / アルカリフォスファターゼ / 分子標的薬 / 分子診断 / ドセタキセル / アンドロゲン除去療法 / 前立腺特異抗原（PSA） / PSAフレア / 前立腺特異抗原(PSA) / オーダーメイド医療 / 遺伝子多型 / ノモグラム |
|---|
| Outline of Final Research Achievements |
In the treatment system for prostate cancer, hormone therapy is widely used not only as the main treatment but also as an adjuvant / combination therapy. The biggest obstacle to hormone therapy is the development of the condition by the acquisition of hormone therapy resistance in cancer cells. Especially in recent years, the importance of the androgen-androgen receptor system has been reaffirmed.
Under these circumstances, in order to provide tailor-made hormone therapy for selecting the optimal treatment method for each patient, in basic research, focusing on the search for the causative protein, in addition to conventional biomarkers, We also analyzed genomic markers such as gene polymorphisms. We also reported clinically including the molecular functional diagnosis of advanced prostate cancer and the report of clinical trial data of new drugs.
|
| Academic Significance and Societal Importance of the Research Achievements |
前立腺癌は、高齢化社会の到来や生活習慣の欧米化もあって、日本においても急増しており、特に発症頻度では男性の悪性腫瘍の上位に位置している。日本の新規前立腺癌患者の約15%程度は転移病期で診断される事から、医学的にも、社会的にも、進行性前立腺癌の病態解明や診断・治療の進歩が急務である。本研究では、進行性前立腺癌の治療体系において、最も重要な選択肢のひとつであるホルモン療法の（去勢）抵抗性の分子生物学的解明と、その治療への応用を目指した、実践的な研究と考える。
|
Report
(6 results)
Research Products
(71 results)
-
[Journal Article] Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.2021
Author(s)
Uemura H, Arai G, Uemura H, Suzuki H, Iijima K, Nishimura K, Fujii K, Hatayama T, Aoyama J, Deprince K, Lopez-Gitlitz A, McCarthy S, Larsen JS, Li J, Chi KN.
-
Journal Title
Int J Urol.
Volume: 28
Issue: 3
Pages: 280-287
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer2018
Author(s)
Smith Matthew R.、Saad Fred、Chowdhury Simon、Oudard St?phane、Hadaschik Boris A.、Graff Julie N.、Olmos David、Mainwaring Paul N.、Lee Ji Youl、Uemura Hiroji、Lopez-Gitlitz Angela、Trudel G?ralyn C.、Espina Byron M.、Shu Youyi、Park Youn C.、Rackoff Wayne R.、Yu Margaret K.、Small Eric J.
-
Journal Title
New England Journal of Medicine
Volume: 378
Issue: 15
Pages: 1408-1418
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
-
-
-
-
[Journal Article] Significant impact of biochemical recurrence on overall mortality in patients with high-risk prostate cancer after carbon-ion radiotherapy combined with androgen deprivation therapy.2016
Author(s)
Kasuya G, Ishikawa H, Tsuji H, Nomiya T, Makishima H, Kamada T, Akakura K, Suzuki H, Shimazaki J, Haruyama Y, Kobashi G, Tsujii H; Working Group for Genitourinary Tumors
-
Journal Title
Cancer
Volume: 122
Issue: 20
Pages: 3225-3231
DOI
NAID
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
-
[Presentation] DAROL: DARolutamide ObservationaL study in non-metastatic castration-resistant prostate cancer (nmCRPC) patinets2020
Author(s)
Yu EY, Piecznonka C, Briganti A, Murphy DG, Lebret T, Luz M, Suzuki H, Thiery-Vuillemin A, Oritiz J, Guan R, Armstrong AJ
Organizer
America Society of Clinical Oncology annual meeting
Related Report
Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] 進行性前立腺癌治療のパラダイムシフト：CSPCからCRPCまでの流れは大きく変わる2017
Author(s)
鈴木啓悦, 加藤精二, 宋本尚俊, 米田慧, 若井健, 岡了, 李芳菁, 内海孝信, 遠藤匠, 西見大輔, 矢野仁, 上島修一, 髙波眞佐治, 神谷直人
Organizer
日本アンドロロジー学会第36回学術大会
Related Report
Invited
-
-
[Presentation] 進行性前立腺癌治療の最新動向～St.Gallen APCCC 2017 からのフィードバック～2017
Author(s)
鈴木啓悦, 杉﨑裕香, 島田悠希, 米田慧, 加藤精二, 宋本尚俊, 若井健, 李芳菁, 岡了, 遠藤匠, 西見大輔, 上島修一, 矢野仁, 神谷直人, 髙波眞佐治
Organizer
第44回尿路悪性腫瘍研究会
Related Report
Invited
-
-
-
[Presentation] 「ＣＲＰＣの薬剤選択：わたしはこう考える」CRPC骨転移症例に対する個別化医療.2017
Author(s)
神谷直人, 加藤精二, 米田慧, 宋本尚俊, 岡了, 李芳菁, 遠藤匠, 矢野仁, 上島修一, 西見大輔, 髙波眞佐治, 鈴木啓悦
Organizer
第105回日本泌尿器科学会総会
Related Report
-
-
-
-
[Presentation] 骨代謝マーカーを利用した去勢抵抗性前立腺癌骨転移症例に対する集学的治療2017
Author(s)
神谷直人, 島田悠希, 杉﨑裕香, 米田慧, 宋本尚俊, 若井健, 岡了, 李芳菁, 遠藤匠, 矢野仁, 上島修一, 西見大輔, 髙波眞左治, 鈴木啓悦
Organizer
第55回日本癌治療学会学術集会
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
